A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Nilotinib (Primary) ; Cetuximab
- Indications Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- 06 Feb 2019 Status changed from recruiting to discontinued.
- 03 Jul 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
- 03 Jul 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.